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Summary: We have developed an assay for 0.2 macroglobulin in amniotic fluid, based on the technique of
Fixed Time Kinetic Immunoturbidimetry. The assay is precise (CV 5% between assays) and has a detection
limit of 0.4 mg/1. We have determined the reference ränge for a? macroglobulin from 100 amniotic fluid
samples from none Neural Tube Defect pregnancies. The data indicates no significant Variation of c*2 macro-
globulin with gestational age and that the results in none Neural Tube Defect pregnancies showed a narrow
reference ränge with a mean of 1.67 mg/1 and + 2 SD ränge of 0.23—3.11 mg/1 (99 percentile = 3.65 mg/1).
Results in 25 Neural Tube Defect pregnancies are presented.
Bestimmung von a.2-Makroglobulin im Fruchtwasser durch „fixed time"-kinetische Immunturbidimetrie
Zusammenfassung: Die Bestimmung von a2-Makroglobulin im Früchtwasser durch "fixed time"-kinetische
Immunturbidimetrie wird beschrieben. Das Verfahren zeigt zwischen den Serien einen Variationskoeffi-
zienten von 5% und hat eine Nachweisgrenze von 0,4 mg/1. Der Referenzbereich für az-Makroglobulin
wurde an 100 Ffuchtwasserproben von Schwangerschaften ermittelt, bei denen kein Neuralrohrdefekt be-
stand. Signifikante Änderungen der aa-Makroglobulinkonzentration mit der Schwangerschaftsdauer wurden
nicht beobachtet, die untersuchten Proben ergaben einen schmalen Referenzbereich mit = 1,67 mg/1 und
± 2s == 0,23-^3,11 mg/1 (99. Perzentil 3,65 mg/1). Die Ergebnisse von Untersuchungen an 25 Schwanger-
schaften mit Neuralrohrdefekt werden mitgeteilt.
Intfoduction
Amniotic fluid -fetoprotein measurements are
widely used äs a follow up to maternal serum a-feto-
protein screening for the detection of neural tube de-
fects. However amniotic fluid -fetoprotein estima-
tions have their limitations. Levels decrease with
l ) Present address; Department of Biochemistry, Oldchurch
Hospital, RomfonJ, Essex, U.K.
gestational age, and if a cut off level of 5 SD above
the mean for normal pregnancies is taken, 10% of
open spina bifida cases may be missed (1). Raised
amniotic fluid -fetoprotein levels are associated
with threatened abortion, fetal death, exomphalos,
congenital nephrosis, Turner's syndrome and several
other disorders. There is a need for additional Infor-
mation to improve the success rate for detection of
neural tube defects and to identify cases with high
results due to other causes.
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The use of concanavalin A affinity Chromatographie
fractionation of a-fetoprotein (2), gel electrophoret-
ic fractionation of cholinesterase activity (3) and ct2
macroglobulin estimations (4) have been proposed
äs possible adjuncts to total amniotic fluid a-fetopro-
tein measurements in the identification of neural
tube defects. The relative merits of the three addi-
tional tests in the evaluation of false positive, bor-
derline and false negative total amniotic fluid a-feto-
protein results have been recently outlined (5, 6).
Measurements of a2 macroglobulin in amniotic fluid
have either involved "rocket" immunoelectrophore-
sis (4, 7) or continuous flow nephelometry (8).
Rocket electrophoresis whilst being sensitive (detec-
tion limit 0.1 mg/1) is time consuming and imprecise
compared with the newer techniques such äs Kinetic
Immunoturbidimetry (9) which are rapid, automata-
ble and almost äs sensitive.
This paper describes the development of an assay for
amniotic fluid 02 macroglobulin by a Fixed Time Ki-
netic Immunoturbidimetric technique and the deter-
mination of reference values.
Materials and Methods
Ins t rumen ta t ion
In this study we used the LKB 2086 Mark II Kinetic Analyser
with Kinetic Data Processor and recorder (Clinicon Systems Ltd.,
Bromma, Sweden).
Reagents
All reagents were obtained from British Drug Houses, Poole,
Dorset, U.K., except where stated.
Phosphate buffer (0.05 mol/1 phosphate, 0.1 mol/1 sodium chlo-
ride, 22.5 mmol/I EDTA, pH 7.40 + 0.02): Dissolve 5.85g of
sodium Chloride, 9.10g of di potassium ethylene diaminetetra
acetate dihydrate, 7.16g of di sodium hydrogen phosphate and
l .33 g of potassium di hydrogen phosphate in 950 ml distilled wa-
ter and dilute to l litre. The buffer is stable at 4 °C for at least one
month.
Phosphate buffer with polyethylene glycol 6000: Dissolve 40 g of
pplyethylene glycol 6000 (PEG) in 800 ml of the above buffer and
dilute to l litre with buffer. This solution is stable at 4 °C for at
least one month.
Stock anti human co macroglobulin antisera: Sheep anti human 012
macroglobulin (Seward Laboratory, UAC House, Blackfriärs
Road, London; Product no. BA 14). Prepare working antiserum
dilutions by making the appropriate dilution with buffer/PEG
reagent, allowing it to stand for 30 minutes at room temperature
and centrifuging (1950g, 10 minutes) to remove any precipitate.
Standards: Standards were prepared from Hoechst Protein Stand-
ard Serum LC-V (Hoechst Pharmaceuticals, Hounslow, U.K.,
Product no. OTFO 02/03), by dilution in 0.1 mol/1 saline to give a
ränge of Standards l mg/l-30mg/l.
Assay Procedures
Table l summarizes the assay arrangements, including Instrument
settings for the Fixed Time Kinetic Immunoturbidimetric proto.
col. The centrifuged sample is preincubated with buffer/PEG dil-
uent at 37 °C for äs long äs 15 minutes before the addition of
diluted antiserum. The change in absorbance in the disposable
7 mm path length cuvets is monitored for 120 seconds on the 0.05
absorbance ränge. The absorbance change (corrected to a 10 mm
path length) for the Standards is used to construct a calibration
curve by parabolic fit using the Data Processor, prior to automatic
calculation of 0.2 macroglobulin concentration in the unknown
samples. The operating progrämme, including cilibrator values
was stored on a tape cassette and coüld be recalled by use of an
analysis code.
The first five tubes in a batch were Standards, followed by uh^
known samples. The data processor presented the Standard curve
äs absorbance changes (corrected to a 10 mm path length) and äs
a slope equation with a correlation coeffkient followed by the re-
spective calculated results for each unknown sample. Alternative^
ly results can be calculated by graphical meäns, with use of the
absorbance change during 120 seconds.
Before priming the reagent pump and tubing in the kinetic analys^
er, we filled the tubing with working antiserum solution and äÜ
lowed it to equilibrate for 10 minutes, the solution was then re-
turned to the reagent bottle and the tubing re-primed.
For comparison purposes the method used was a modification of
the electroimmunoassay method of Laufell (10), using the Seward
antiserum.
Tab. l, Assay settings for amniotic fluid 0:2 macroglobulin assay.
Antiserum
Seward sheep anti human 0.2 macroglobulin diiuted four fold with
polyethylene glycol 6000 (PEG)/phosphate buffer.
Kinetic Analyser variables
Buffer/PEG 300








Measuring interval 120 seconds
Results
Several factors affect the antigen/antibody reaction
and these have been described in detail elsewhere (9,
11,12,13). Reäctiofi conditions investigated include
pH, temperature, sodium chlöride concentration and
polymer (polyethylene glycol 6000) concentration.
Each parameter was shown to have similar optima tö
those indicated for other assays (9, 11-13).
The calibration curves for four separate assays are
sümmärised in figure 1. The recorder Output from a
typical calibrätion curve is shown in figure 2, along^
side three samples — sample A from a normal pfeg^
nancy, sample B from an neural tube defect preg^
nancy with an 012 macroglobulin level within the
ränge of the assay, sample C from a neural tube de-
fect pregnancy with an 012 macroglobülin level out-
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Fig. l. dz macroglobulin calibration curve for four separate runs.
Each point shows ± s.





Fig. 2. Chart rccording depicting a normal calibration curve fol-
lowed by threc samples,
A = Normal prcgnancy
B Neural Tube Defect pregnancy with aa macroglobulin
within*the assay ränge
C — Neural Tube Defect pregnancy with (12 macroglobulin
outside the assay ränge.
side the ränge of the assay. Curve C is a characteris-
tic curve for a sample which has produced an antigen
excess Situation and äs such is instantly recognisable
and would be repeated with subsequent dilution of
the sample.
Detection l imi t
The minimum detectable concentration of macro-
globulin in the assay System was determined by dilut-
ing a high neural tube defect specimen with a solu-
tion of human serum albumin (10 g/l). The detection
limit corresponded to an 0.2 macroglobulin concen-
tration of 0.4 mg/1 giving an absorbance change of
0.005 A per 120 secoiids.
Method performance
Precision
Within run precision of the assay System was as-
sessed by measuring replicates (n = 20) of three
samples with different a2 macroglobulin levels; at
1.1 mg/1 the CV was 5.8%, at 3.1 mg/1 the CV was
4.7% and at 23.8 mg/1 the CV was 1.9%.
Between run precision was assessed by analysing se-
parate frozen aliquöts (n = 10) of the samples. On
each occasion a fresh dilution of antiserum was pre-
pared. At a concentration of 3.4 mg/1 the CV was
5.2% and 2.8% at 24.6 mg/1.
Accuracy
The IFCC Expert Panel on Nomenclature and Prin-
ciples of Quality Control in Clinical Chemistry (14)
recommends that method accuracy be assessed by
using recovery checks with pure analyte and also by
comparing the values obtained with samples assayed
by a method of known accuracy. Because there is no
internationally agreed upon Standard or pure az ma-
croglobulin available, accuracy could only be as-
sessed by the latter method.
We compared patient samples analysed by the pro-
posed method with the electroimmunoassay proce-
dure. The regression parameters according to the
Deming procedure were; y = 0.89 + 0.05 (r =
0.918, n = 40).
Reference ränge
Amniotic fluid specimens over a wide ränge of gesta-
tional age were kindly supplied by the Regional Cen-
tre, Department of Cytogenetics, Salisbury General
Infirmary and were stored at -20 °C prior to analy-
sis. Detailed study of the patients notes were taken
. after the birth to exclude any potentially abnormal
samples. The samples were analysed for 0.2 macro-
globulin concentration spread over six separate as-
says.
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The mean results for each weck of pregnancy are
shown in table 2 and the individual results plotted on
a log scale in figure 3. These results indicate a very
narrow normal ränge, with an overall mean level öf
1.67 mg/1, +2 SD ränge of 0.23-3.11 mg/1 and a
99th centile of 3.65 mg/1. Furthermore the levels are
independent of gestational age. These findings agree
very closely with those of Haddow et al. (8) who also
showed a mean of l .7 mg/1 and Van Kamp et al. (7)
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Fig. 3. Variation of normal amniotic fluid a2 macroglobulin levels
with gestational age plotted on a log scale.
Clinical application
Amniotic fluid specimens from 25 known neural
tube defect pregnancies were submitted for 0.2 ma-
croglobulin analysis. The results relative to the refer-
ence ränge are plotted on a log scale in figure 4. The
data clearly showes the Separation of normal preg-









Fig. 4. 0:2 macroglobulin levels in 25 known Neural Tube Defect
affected pregnancies.
Conclusions
A quick reliable assay for 0.2 macroglobulin has been
developed and assessed using the technique of Fixed
Time Kinetic Immunoturbidimetry. The reference
ränge frpm 97 normal pregnancies has been shown
to be 0.23-3.11 mg/1 (mean -2 SD, 99tti centile
3.65 mg/1). The test has proven useful in providing
additional Information concerning the likely out-
come of pregnancies presenting with equivocal ain-
niotic fluid -fetoprotein levels. The data concerning
this clinical study has been preseiited elsewhere (5,
6). The main drawbaek to the use of 0.2 macroglobul-
in assays in this way lies in the potential interference
by maternal blood contamination since levels of 0.2
macroglobulin are 103 fold greater in maternal se-
rum (4). Prior screening of samples for blood coiitä-
minatiön excluded such samples from contributing to
the reference ränge.
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